Advertisement

Topics

Efficacy and Safety With Ziprasidone in First-episode Psychosis

2010-07-15 17:00:00 | BioPortfolio

Summary

The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

First Episode Psychosis

Intervention

Ziprasidone

Location

Department of Psychiatry, Chonbuk national University Hospital
Jeonju
Korea, Republic of

Status

Completed

Source

Chonbuk National University Hospital

Results (where available)

View Results

Links

Published on BioPortfolio: 2010-07-15T17:00:00-0400

Clinical Trials [335 Associated Clinical Trials listed on BioPortfolio]

A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

The purpose of this study is to evaluate the efficacy and tolerability of ziprasidone in patients who successfully completed a study of ziprasidone treatment of psychosis (Protocol A128107...

Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up

The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment ...

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, ...

Ziprasidone in the Psychosis Prodrome

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Role of Minocycline in First Episode Psychosis

The purpose of this study is to determine whether the addition of minocycline or placebo to treatment as usual (TAU): 1. prevents the accumulation of negative symptoms and intellectual ...

PubMed Articles [591 Associated PubMed Articles listed on BioPortfolio]

Obesity, dyslipidemia and brain age in first-episode psychosis.

Obesity and dyslipidemia may negatively affect brain health and are frequent medical comorbidities of schizophrenia and related disorders. Despite the high burden of metabolic disorders, little is kno...

Early interventions in a US military FIRST episode psychosis program.

Naval Medical Center San Diego's Psychiatric Transition Program is a specialized first episode psychosis treatment program that delivers coordinated specialty care to military service members with psy...

Sexually dimorphic subcortical brain volumes in emerging psychosis.

In schizophrenic psychoses, the normal sexual dimorphism of the brain has been shown to be disrupted or even reversed. Little is known, however, at what time point in emerging psychosis this occurs. W...

Physical and psychological health of carers of young people with first episode psychosis.

Carers of people with psychosis may experience psychological distress and caregiving burden. However, few studies have examined both psychological and physical health of carers of young people with fi...

The supportive care needs of individuals recovering from first episode psychosis: A scoping review.

First episode psychosis (FEP) can be a traumatic experience that may alter an individual's ability to meet their own needs. The Supportive Care Needs Framework (SCNF) could complement the recovery-ori...

Medical and Biotech [MESH] Definitions

An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode but that does not usually result in MYOCARDIAL INFARCTION.

Reactions to an event or set of events which are considered to be of pathological degree, that have not developed into a neurosis, psychosis, or personality disorder with fixed patterns.

A highly toxic compound used as a gasoline additive. It causes acute toxic psychosis or chronic poisoning if inhaled or absorbed through the skin.

One of the FLAVORING AGENTS used to impart a meat-like flavor. Medically it has been used to reduce blood ammonia levels in ammoniacal azotemia, therapy of hepatic coma, in psychosis, and mental retardation.

Capacity that enables an individual to cope with and/or recover from the impact of a neural injury or a psychotic episode.

More From BioPortfolio on "Efficacy and Safety With Ziprasidone in First-episode Psychosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial